#APOC3

Thiard News@F4F

@newsen.bsky.social

4 months ago

Rona Therapeutics Unveils Promising Phase 1 Results of RN0361 at AHA 2025 Scientific Sessions Rona Therapeutics showcased the promising Phase 1 data of RN0361 at the AHA 2025, indicating a potential breakthrough in treating hypertriglyceridemia.

Rona Therapeutics Unveils Promising Phase 1 Results of RN0361 at AHA 2025 Scientific Sessions #USA #New_Orleans #Rona_Therapeutics #RN0361 #APOC3

Khanh-Van T Tran, MD PhD

@kvtran.bsky.social

4 months ago

Incredibly exciting and helpful updates in our space from Dr Tsimikas! (UMass Chan alum 😁) #APOC3 #sTG #AHA25

Khanh-Van T Tran, MD PhD

@kvtran.bsky.social

4 months ago

Remarkable, groundbreaking progress for cardiometabolic science and medicine!!! #FGF21R #GLP1 #APOC3 #ANGPTL3 #PCSK9 #mAb #siRNA #ASO #CRISPRCas9
Shoutout to ♥️ basic and clinical scientists moving this forward for our patients! @ahascience.bsky.social #AHA25 #PrevCards #Lipidology

Thiard News@F4F

@newsen.bsky.social

4 months ago

First Gene-Editing Therapy Targeting APOC3 Marks a Milestone for Hyperlipidemia Treatment CorrectSequence Therapeutics has achieved a groundbreaking milestone by successfully administering the first-ever gene-editing therapy targeting APOC3 for hyperlipidemia patients. This innovation could mean a significant shift in treatment protocols.

First Gene-Editing Therapy Targeting APOC3 Marks a Milestone for Hyperlipidemia Treatment #China #Shanghai #CorrectSequence #Hyperlipidemia #APOC3

Thiard News@F4F

@newsen.bsky.social

4 months ago

World's First Gene-Editing Therapy for Hyperlipidemia Approved CorrectSequence Therapeutics announces a groundbreaking gene-editing treatment targeting APOC3 for hyperlipidemia, marking a significant medical milestone.

World's First Gene-Editing Therapy for Hyperlipidemia Approved #China #Shanghai #Gene_Editing #CorrectSequence #APOC3

Thiard News@F4F

@newsen.bsky.social

4 months ago

First Ever Gene-Editing Therapy for Hyperlipidemia Achieves Key Milestone CorrectSequence Therapeutics has made a historic innovation by administering the first gene-editing therapy aimed at treating hyperlipidemia. Learn more about this groundbreaking advancement.

First Ever Gene-Editing Therapy for Hyperlipidemia Achieves Key Milestone #China #Shanghai #CorrectSequence_Therapeutics #CS-121 #APOC3

Krit Krat

@krittkratt.bsky.social

1 year ago

Yesterday when I was attempting Apoc 3 again at Sunny Meadows on Phasmophobia...

Got a Blood Moon on the day of the actual Blood Moon... 🥴

Instant reset...

#phasmophobia #apoc3 #bloodmoon

Shicheng Guo

@shihcheng.bsky.social

1 year ago

In a 48-week trial, Plozasiran, an RNA interference agent targeting APOC3, significantly reduced triglyceride-rich lipoproteins and improved lipid profiles in mixed hyperlipidemia patients. #APOC3 #CardioCare PMID:38804517, N Engl J Med 2024